Results for: Lung

36 Trials Avaliable

  • LUN 196

    TOPPS (Trial Of Poor Performance Status patients): Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients with Stage III/IV Non'Small-Cell Lung Cancer and ECOG Performance Status 2

  • LUN 296

    A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (Anti-PDL1 ANTIBODY) COMPARED WITH CISPLATIN OR CARBOPLATIN+PEMETREXED FOR PD-L1-SELECTED CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

  • LUN 303

    Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin Chemotherapy

  • LUN 306

    A phase II, multicenter, two-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), cMET- amplified, advanced non-small cell lung cancer (NSCLC) who have received one to three prior lines of systemic therapy for advanced/metastatic disease

  • LUN 308

    A Phase III, Open label, Randomized Study to Investigate the Efficacy and Safety ofMPDL3280A (Anti-PDL1 Antibody) Compared With Standard of Care Following Adjuvant Cisplatin-based Chemotherapy in PDL-1 Selected Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

  • LUN 325

    A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)

  • LUN 376

    An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1/PD-L1 Containing Therapy (HUDSON)

  • LUN 391

    A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer

  • LUN 395

    A Phase 1 Study of SC-011 as a Single-Agent and in Combination with ABBV-181 in Subjects with Relapsed or Refractory Small Cell Lung Cancer

  • LUN 417

    Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated advanced Non Squamous Non-Small Cell Lung Cancer participants with CEACAM5 positive tumors

  • LUN 434

    A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib

  • LUN 437

    Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

  • LUN 442

    A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLEDSTUDYOF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUSPEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUSPEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON?SMALL CELL LUNG CANCER

  • LUN 444

    A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a SingleAgent and In Combination with Defactinib (FAK Inhibitor) in RecurrentKRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)

  • LUN 468

    A Phase 2, Open-Label, Multicenter Study of the Combination ofRMC-4630 and Sotorasib for Non-Small Cell Lung CancerSubjects with KRASG12CMutation After Failure of Prior StandardTherapies

  • LUN 470

    A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046as Monotherapy and in Combination With Anti-cancer Therapy inSubjects With Relapsed/Refractory Metastatic Non-Small Cell LungCancer After Treatment With Standard of Care Therapy With anImmune Checkpoint Inhibitor

  • LUN 472

    A Phase 1b/2, multicenter, single arm study of RBN-2397 in combination with pembrolizumab in patients with Squamous Cell Carcinoma of the Lung (SCCL)

  • LUN 475

    A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF LURBINECTEDIN PLUS ATEZOLIZUMAB COMPARED WITH ATEZOLIZUMAB AS MAINTENANCE THERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC) FOLLOWING FIRST-LINE INDUCTION THERAPY WITH CARBOPLATIN, ETOPOSIDE AND ATEZOLIZUMAB

  • LUN 476

    Open-Label, Global, Multicenter, Randomized, Phase 3 Study ofSacituzumab Govitecan Versus Docetaxel in Patients WithAdvanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)With Progression on or After Platinum-Based Chemotherapy andAnti-PD-1/PD-L1 Immunotherapy

  • LUN 478

    A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

  • LUN 480

    A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB05CB054828 in Subjects With Advanced Non-Small Cell Lung Cancer with an FGFR Alteration Who Failed Previous Therapy (FIGHT-210)

  • LUN 482

    A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

  • LUN 483

    A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Chiauranib for the Treatment of Relapsed/Refractory Small Cell Lung Cancer

  • LUN 489

    A Phase 1 Open-Label Study of U3-1402 in Combination with Osimertinib in Subjects with Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

  • LUN 490

    HERTHENA-Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy

  • LUN 492

    A Randomized, Open-label Phase 2 Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

  • MULTI 04

    An Open-Label, Multicenter, Phase 1 Study of Ramucirumabplus Pembrolizumab in Patients with Locally Advanced andUnresectable or Metastatic Gastric or GastroesophagealJunction Adenocarcinoma, Non-Small Cell Lung Cancer, orTransitional Cell Carcinoma of the Urothelium

  • OUTCOMES 13

    EGFR-tested Non-Small-Cell Lung Cancer Patients Treated with Erlotinib Six Months or Longer: Demographics, Treatment and Outcome Characteristics of Patient Cases in a Community-Based Setting

  • PRO 16

    Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 skip mutations and c-Met Dysregulation Advance Solid Tumors

  • RM 401

    A Phase 1B/2, Open-label, Dose Escalation Study of Entinostat plus a PD1/PDL1-blocking Antibody in Patients with Melanoma and Non-small Cell Lung Cancer

  • RM 501

    A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity

  • RM 557

    A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

  • RM 671

    A Phase 1 study of FF-10850, topotecan liposome injection, in advanced solid tumors including ovarian and cervical carcinoma, sarcomas, and neuroendocrine tumors including small cell lung cancer.

  • RM 858

    A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer

  • RM 929

    A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF ORAL MRT-2359 IN PATIENTS WITH MYC-DRIVEN AND OTHER SELECTED SOLID TUMORS INCLUDING LUNG CANCER AND DIFFUSE LARGE B-CELL LYMPHOMA

  • SMILE

    Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients (SMILE')